Markets plunged more than 670 points, logging the worst week in 2 years. Lindsey Bell, Investment Strategist at CFRA Research, was with us to break down the factors causing stocks to tumble.
A positive jobs report that revealed 200,000 jobs in January and a 2.9% increase in wages are giving the Fed more ammo in its case to raise rates at a faster pace. It's not just rates that are a cause of concern, said Bell. The analyst said we are seeing China had a tough week over concerns over economic growth and financial regulation.
Bell said we also can't underestimate the impact the release of the GOP surveillance document had on the markets. This is a form of uncertainty, which could lead to investors pulling money out of the markets, she added. Bell said she thinks this is a healthy move downward and profit-taking is probably necessary. She said a 10% pullback could be in the cards.
Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.
Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Supermarket chain Ralphs is facing a new lawsuit from the state of California.
Shake Shack is giving out free fried chicken sandwiches, bacon cheese fries and milkshakes nationwide.
The IRS is announcing a voluntary disclosure program.
Lionsgate announced its studio division is going to spin off in a merger with Screaming Eagle Acquisition Corp., which is a special purpose acquisition company.
A new report suggests that it's getting more difficult for an average American to afford a home.
The Food and Drug Administration warned consumers about a copycat version of the diabetes drug Ozempic.
